NEUROPEPTIDE RESEARCH

Selank: Anxiolytic Peptide Research and GABA Pathway Modulation

Velox Peptides Research Team·Published May 2026·6 min read
CAS Number
129954-34-3
Peptide Class
Tuftsin analogue
Key Pathway
GABAergic / BDNF
HPLC Purity
≥98.9% (batch-verified)
For in vitro research use only. Selank is supplied solely as a research reagent for in vitro use and is not for human or veterinary consumption. This page is a literature summary, not medical advice.

What is Selank?

Selank is a synthetic heptapeptide developed in Russia at the Institute of Molecular Genetics, based on the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with an added Pro-Gly-Pro sequence that improves stability against enzymatic degradation. It is studied primarily as an anxiolytic (anti-anxiety) research peptide.

Like its frequently paired counterpart Semax, Selank comes from a substantial Eastern European research tradition and is used as a neuropeptide reagent for studying peptide modulation of behaviour and stress responses in animal models.

GABAergic and neurotrophic signalling

GABA pathway modulation. Preclinical studies associate Selank with modulation of the GABAergic system — the brain’s principal inhibitory neurotransmitter pathway — which is a common research target for anxiolytic activity. Rodent models have examined Selank’s association with reduced anxiety-like behaviour without the sedation typical of classical GABA-A modulators.

BDNF and monoamine signalling. Research has also examined Selank’s association with brain-derived neurotrophic factor (BDNF) expression and with serotonergic signalling, as well as its reported effect on the stability of enkephalins (endogenous opioid peptides) by influencing their enzymatic breakdown.

Selank and Semax

Selank is frequently studied alongside Semax in cognitive and neuropeptide research. The two are associated with complementary pathways — Semax with neurotrophic (BDNF/NGF) signalling and Selank with GABAergic and anxiolytic modulation — so they are often examined together. See the Semax research overview for the paired mechanism. Both sit within neuropeptide research.

Velox Peptides supply information

Velox Peptides supplies Selank as a lyophilised powder at ≥98.9% HPLC-verified purity with a batch certificate of analysis available on request. For reconstitution, see the reconstitution calculator. Supplied strictly as a research reagent for in vitro use.

References & further reading

  1. Kozlovskaya MM, Kozlovskii II, Val’dman EA, Seredenin SB. “Selank and short peptides of the tuftsin family in the regulation of adaptive behaviour.” Neuroscience and Behavioral Physiology, 2003.
  2. Zozulia AA et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank.” review literature, 2008.

Summaries are paraphrased from the peer-reviewed literature. For full source citations, email veloxpeps@gmail.com.

Frequently asked questions

What is Selank?
Selank is a synthetic heptapeptide analogue of tuftsin, developed in Russia and studied as an anxiolytic neuropeptide research reagent. Velox Peptides supplies it for in vitro research use only.
What pathway is Selank associated with?
In preclinical models Selank is most associated with modulation of the GABAergic (inhibitory) system and with BDNF and serotonergic signalling.
Why is Selank studied with Semax?
They are associated with complementary neuropeptide pathways — Selank with GABAergic/anxiolytic modulation and Semax with BDNF/NGF signalling — so researchers often pair them.
What purity is Velox Peptides Selank?
Selank is HPLC-verified at a minimum of 98.9% purity, with batch documentation available on request.
Is Selank legal to buy in the UK?
Yes — for in vitro research purposes. It is not a licensed medicine and not for human use. Velox Peptides supplies it solely as a research reagent.
Compliance statement. Velox Peptides supplies research reagents for in vitro use by qualified researchers. Every compound is sold strictly as a research reagent. No product is a medicinal product within the meaning of the Human Medicines Regulations 2012. No product has been evaluated by the MHRA or FDA. No product is intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Any use outside lawful scientific research is outside the scope of sale. See our Research Use Policy and MHRA Statement.

All research summaries on this page are derived from publicly available peer-reviewed literature. Velox Peptides makes no therapeutic claims. For research use only.